Table 1.

Baseline demographic characteristics of the observational cohort. Data are mean ± SD or number (%).

Characteristics	Classic Responders	Nonresponders	Short-term Re-therapy
Age, yrs^*	55.05 ± 9.79	52.00 ± 10.49	45.00 ± 16.00
Female, %^**	78.95	71.43	83.33
Disease duration, yrs^*	10.89 ± 7.43	15.79 ± 16.75	8.67 ± 6.31
Rheumatoid factor and/or ACPA-positive, %^**	89.47	85.71	66.67
Radiographic erosive disease, n (%)^**	10 (52.63)	9 (64.29)	3 (50.00)
Radiographic non-erosive disease, n (%)^**	3 (15.79)	2 (14.29)	3 (50.00)
Radiographic not specified, n (%)^**	6 (31.58)	3 (21.43)	0 (0.00)
Previous DMARD, more than one, n (%)^**	10 (52.63)	10 (71.42)	5 (83.33)
Previous DMARD, one, n (%)^**	4 (21.05)	1 (7.14)	1 (16.66)
Previous DMARD, none or not specified, n (%)^**	5 (26.32)	3 (21.43)	0 (0.00)
Previous biologics, more than one anti-TNF agent, n (%)^**	10 (52.63)	6 (42.86)	5 (83.33)
Previous biologics, one anti-TNF agent, n (%)^**	9 (47.37)	5 (35.71)	1 (16.66)
Previous biologics, IL-1 receptor antagonist, n (%)^**	3 (15.79)	1 (7.14)	0 (0.00)
Previous biologics, none or not specified, n (%)^**	4 (21.05)	3 (21.43)	0 (0.00)
Extraarticular manifestation of RA, n (%)^**	5 (26.32)	7 (50.00)	1 (16.66)
Rheumatoid nodules, n (%)^**	4 (21.05)	7 (50.00)	1 (16.66)

↵* No significant differences between groups (Mann-Whitney U test);
↵** No significant differences between groups (chi-square test). ACPA: anti-citrullinated protein/peptide antibodies; DMARD: disease-modifying antirheumatic drug; IL: interleukin; TNF: tumor necrosis factor.